Discussion: View Thread

Molecule Focus: Bispecific Antibody (BsAb) - Explore All BsAb Resources in One Convenient Hub

  • 1.  Molecule Focus: Bispecific Antibody (BsAb) - Explore All BsAb Resources in One Convenient Hub

    Posted 27-05-2025 04:49 PM
    As of 2025, the bispecific antibody (BsAb) market exceeds USD 10 billion, fueled by multiple FDA approvals and 300+ clinical candidates. BsAbs now go beyond T-cell engagers to include NK cell engagers, dual checkpoint inhibitors, receptor clustering agents, and tumor-targeted cytokines, with formats ranging from IgG-like to trispecific and Fc-silent designs. 
     
    With innovation spanning discovery, process development, and manufacturing, understanding the full bsAb development continuum is critical. For scientists, developers, and decision-makers, learning this integrated landscape is essential to reduce R&D risk, accelerate timelines, and capture opportunity in one of the most competitive and transformative biologics sectors today.
    🔬What to Learn:
    1. Start Strong with BsAb Discovery
    White Paper: How to Design and Evaluate BsAbs
    • What are BsAbs?
    • How to design discovery strategies based on structure?
    • How to evaluate BsAbs comprehensively by MOA?
    •  
    2. Reliable Cell line development
    Poster: Optimized Vector System for BsAb Expression in CHO-K1 Cells
    White Paper: Cell Line Development Strategies for BsAb Manufacturing
     
    3. Accelerated CMC Development
    Folding: From Sequence to Tox DS Release in 7 Months for Symmetrical BsAb
    White paper: Analytical Approach for BsAb Quality Study
     
    4. Smooth tech transfer and qualified manufacturing
    Handbook: Tech Transfer Manual
    Folding: GMP Manufacturing Solutions
     
    5. Proven Success
    By providing a comprehensive suite of CMC development and IND dossier services, ProBio supported IMBiologics in obtaining FDA clearance and achieving a smooth license-out.
    • 2023 ProBio Congratulates IMBiologics on FDA Clearance of IND Application for Innovative Bispecific Antibody Drug Project (IMB-101)
    • 2024 IMBiologics Licenses $925mn Antibody Treatment (IMB-101) to Navigator Medicines
     
    6. On-demand webinar
    • Multiple Solutions of Functional Leads Discovery and Engineering
    • ProBox™ Platform for Complex Biologics CMC Development
    • Navigating Biologics Challenges:Regulatory, Process Development, and Tech Transfer Solutions 
     



    ------------------------------
    Jessica Tu
    Regional Marketing Manager
    ProBio
    ------------------------------